Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). BeiGene's share price for the quarter that ended in Mar. 2024 was HK$95.1. BeiGene's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 1,358 Mil. Therefore, BeiGene's market cap for the quarter that ended in Mar. 2024 was HK$129,181 Mil.
BeiGene's quarterly market cap
increased
from Sep. 2023 (HK$145,583 Mil) to Dec. 2023 (HK$149,682 Mil) but then
declined
from Dec. 2023 (HK$149,682 Mil) to Mar. 2024 (HK$129,181 Mil).
BeiGene's annual market cap
declined
from Dec. 2021 (HK$214,903 Mil) to Dec. 2022 (HK$181,994 Mil) and
declined
from Dec. 2022 (HK$181,994 Mil) to Dec. 2023 (HK$149,682 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. BeiGene's Enterprise Value for Today is HK$120,789 Mil.
BeiGene Market Cap Historical Data
The historical data trend for BeiGene's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BeiGene's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeiGene's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeiGene's Market Cap distribution charts can be found below:
* The bar in red indicates where BeiGene's Market Cap falls into.
BeiGene Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
BeiGene's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeiGene (HKSE:06160) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
BeiGene Market Cap Related Terms
Thank you for viewing the detailed overview of BeiGene's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:06160 has been successfully added to your 